Spyre Therapeutics, Inc.
NASDAQSpyre Therapeutics enters the final days of August with a striking split between what options traders are signalling and what short sellers are doing — a divergence that makes this week's setup unusually hard to read. The clearest tension is in the options market. Put buying has gone parabolic relative to recent norms. The put/call ratio hit 4.82 on Tuesday — the highest reading of…
SYRE put/call ratio crashes to 0.27, lowest in 52 weeks, as bullish options flow overwhelms bearish bets amid 35% monthly surge.
Snapshot as of 20 Sept 2026
Spyre Therapeutics enters the final days of August with a striking split between what options traders are signalling and what short sellers are doing — a divergence that makes this week's setup unusually hard to…
Spyre Therapeutics enters the post-earnings stretch with an unusual alignment: analysts racing to raise targets, short sellers steadily trimming positions, and the stock up 21% over the past month to $104.94. The…
Spyre Therapeutics enters the back half of June with a striking tension: the stock has rallied 16% in a week and 31% in a month, yet nearly a fifth of its free float remains borrowed against it. The options market has…
Spyre Therapeutics enters June with an unusual combination: a stock that has drifted 6% lower on the week while the Street is broadly bullish, insider selling has been persistent, and short positions have quietly…
Spyre Therapeutics heads into its May 8 earnings call in a charged position — the Street is racing to lift targets after strong Phase 2 data, while the CEO, CFO, and CMO all hit the sell button on the same day the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SYRE — free to start on ORTEX.
Sign up for free →Open SYRE on ORTEX